Research Analysts Offer Predictions for OCUL Q1 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Research analysts at William Blair issued their Q1 2025 earnings estimates for shares of Ocular Therapeutix in a research note issued to investors on Tuesday, April 8th. William Blair analyst L. Hanbury-Brown forecasts that the biopharmaceutical company will earn ($0.31) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. William Blair also issued estimates for Ocular Therapeutix's Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.23) EPS and FY2026 earnings at ($1.16) EPS.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million.

OCUL has been the topic of several other reports. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Royal Bank of Canada initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They set an "outperform" rating and a $17.00 target price for the company. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research note on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.38.

Remove Ads

Ocular Therapeutix Trading Down 5.4 %

OCUL stock traded down $0.41 during mid-day trading on Friday, hitting $7.12. 732,495 shares of the company were exchanged, compared to its average volume of 1,568,434. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $1.13 billion, a P/E ratio of -5.39 and a beta of 1.49. The business has a fifty day simple moving average of $7.23 and a 200-day simple moving average of $8.56. Ocular Therapeutix has a 12-month low of $4.06 and a 12-month high of $11.78.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Donald Notman sold 11,119 shares of the firm's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the sale, the insider now directly owns 193,444 shares in the company, valued at $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,895 shares of company stock valued at $283,772. 3.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ocular Therapeutix

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Asset Management L.P. lifted its position in shares of Ocular Therapeutix by 43.9% during the 4th quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock worth $25,073,000 after buying an additional 895,304 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Ocular Therapeutix during the fourth quarter valued at approximately $3,819,000. FMR LLC increased its stake in Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company's stock valued at $3,779,000 after purchasing an additional 428,335 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Ocular Therapeutix in the first quarter worth approximately $2,505,000. Finally, Artisan Partners Limited Partnership raised its holdings in shares of Ocular Therapeutix by 26.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock valued at $11,398,000 after purchasing an additional 278,610 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.